Introduction
The microtubular network represents an important target for treating prostate cancer, particularly advanced castration resistant disease. Although the microtubule-targeting agent docetaxel has improved overall survival in men with metastatic prostate cancer, not all patients respond to it (Berthold et al., 2008; Petrylak et al., 2004; Tannock et al., 2004) . Even for men who respond to docetaxel, the treatment is primarily palliative as most experience disease progression within a few months. To improve upon response rates and response duration, a number of agents have been evaluated in various combinations with docetaxel. However, to date, no docetaxel-based combination regimen has been shown to be superior to single agent docetaxel in castration resistant prostate cancer (CRPC) in phase III trials. Importantly, the overall landscape for patients with metastatic CRPC is beginning to gradually change with the recent approval of several therapies, including sipuleucel-T, cabazitaxel, abiraterone, and denosumab (de Bono et al., 2010; de Bono et al., 2011; Fizazi et al., 2011; Kantoff et al., 2010) . Despite such progress, most men with metastatic prostate cancer are likely to eventually succumb to their disease.
We undertook the present study in an effort to better understand some of the adaptive responses of prostate cancer to the taxanes, and to identify new targets that could potentially be exploited for better therapeutic effect in both drug-sensitive and drug-resistant prostate cancer cells. Using DU145 cells as a model of androgen independent prostate cancer, a series of cell lines with varying levels of resistance to both paclitaxel and docetaxel were developed to study the adaptive responses to taxane selection. As telomere length maintenance is implicated in resistance to certain cytotoxic agents, we also investigated telomere dynamics in the above models (Burger and Harnden, 1998; Deschatrette et al., 2004; Ishibashi and Lippard, 1998; Mo et al., 2003; Multani et al., 1999; Smith et al., 2009 ). Since prostate cancer cells have short telomeres and hence may be particularly susceptible to telomere disrupting agents, we evaluated the role of targeting telomeres in both taxane-sensitive and taxane-resistant prostate cancer cells. These studies were extended to androgen-sensitive LNCaP and androgen-insensitive LNCaP/C81 cells.
In this report, we demonstrate that 1) considerable heterogeneity with respect to resistance mechanisms exists within the paclitaxel-and docetaxel-selected DU145 cell populations although they share a common phenotype of resistance to taxanes, 2) telomerase activity and telomere lengths are not significantly altered between drug-sensitive and drug-resistant DU145 cells, and they remain sensitive to a telomere targeting arsenical compound, KML001 (NaAsO 2 , sodium metaarsenite), irrespective of the underlying resistance mechanisms, 3) KML001 can decrease telomerase gene expression and cause erosion of telomeres, and is synergistic with both paclitaxel and docetaxel in wt as well as highly taxane-resistant prostate cancer cells, and 4) this synergism extends to the androgen-sensitive LNCaP as well as the androgen-insensitive LNCaP/C81 cells under both basal and androgen-deprived conditions. These studies provide a This article has not been copyedited and formatted. The final version may differ from this version. Side Population Assay, Cell Immunostaining and Cell Sorting. The side population (SP) assay was carried out according to the method of Goodell et al (Goodell et al., 1996) . Cells were trypsinized and 0.5 x 10 6 cells resuspended in 1 ml medium containing Hoechst 33342 (5 µg/ml) (Burger, 2002) . After adding stop solution, mean absorbance of the samples at 450 nm was determined using a microtiter plate reader (Synergy 2, Biotek, Winooski, VT).
Mean Telomeric Restriction Fragment Length (TRF) Analysis.
Mean TRF lengths were determined using the TeloTAGGG-Telomere length kit as per the manufacturer's instructions.
Genomic DNA was isolated using a DNA extraction kit (Qiagen, Hilden, Germany). 2 μ g of DNA was digested with Hinf1 and Rsa1 for 2 hours at 37°C and loaded onto 0.8% agarose gels.
The DNA was transferred to nylon membranes, hybridized to a digoxigenin-labeled telomere This article has not been copyedited and formatted. The final version may differ from this version. probe, and the telomere related signals detected by chemiluminescence as described previously (Burger et al., 2005) . Quantification of γ-H2AX foci induction was determined by measuring mean fluorescence intensity of at least 100 nuclei in each chamber.
Real Time Polymerase Chain Reaction (RT-PCR
This article has not been copyedited and formatted. The final version may differ from this version. Exposure to increasing concentrations of a particular taxane (paclitaxel or docetaxel) results in increasing resistance not only to the selecting drug but also cross-resistance to the other taxane not used for the original selection (Table 1) . Interestingly, it appears that the DU145 cells are prone to developing higher levels of resistance to docetaxel than to paclitaxel irrespective of the original taxane used for selection. For instance, DU145/Pac10 and DU145/Pac200 cells are 24-and 140-fold resistant, respectively, to paclitaxel (which was used to select them), but are 100-and 400-fold cross-resistant to docetaxel (Table 1) . DU145/Doc10 and DU145/Doc60 cells are 100-and 500-fold resistant, respectively, to their selecting drug, i.e. docetaxel, but are only 24-and 100-fold cross-resistant to paclitaxel.
Both paclitaxel and docetaxel are known substrates of Pgp. This transporter is minimally expressed in wt DU145 cells but it becomes significantly over expressed in the taxane-resistant cells, particularly at the higher levels of drug selection (Fig 1a) . The other ABC transporter, BCRP, is expressed in both wt and resistant cells, but its levels are not modulated with selection for resistance to the taxanes (Fig 1a) . Flow cytometry reveals that Pgp is expressed on the cell surface of a significant fraction of the DU145/Pac200 (79% ± 6.5) and DU145/Doc60 (47 % ± 4.9) cell populations (Fig 1b) . BCRP, on the other hand, is essentially undetectable on the surface of these cells (Fig 1b) . This is further confirmed by immunohistochemistry, which
This article has not been copyedited and formatted. The final version may differ from this version. to drug transport function. This is confirmed by flow cytometry using the 'side population' (SP) assay developed by Goodell et al (Goodell et al., 1996) . The SP fraction is functionally defined by the extrusion of vital dyes such as Hoechst 33342 due to enhanced expression of ABC transporters (Goodell et al., 1996) . The SP fraction can be enriched in stem/progenitor cells, and generally represents a very small portion of the total population; for instance it comprises approximately 0.1% of all nucleated cells in the bone marrow of mice, where it corresponds largely to hematopoietic stem cells.
Parental DU145 cells have a small SP fraction (0.4-1.2 %) (Fig 2a) . This fraction increases in the cell lines selected for increasing resistance to docetaxel; it is approximately 20% in DU145/Doc10 and 60% in DU145/Doc60 cell populations, respectively (Fig 2a) . Pgpdependent exclusion of the dye was confirmed by treating these cells with verapamil (VP).
Although VP is a potent inhibitor of L-type calcium channels, it also inhibits Pgp but not BCRP function. It has been used by investigators to assess Pgp-dependent transport (Tsuruo et al., 1981; Grossi and Biscardi, 2004) . As seen in Fig (Fig 2b) . The BCRP-specific inhibitor Ko143, on the other hand, has no effect on Hoechst 33342 uptake (Fig 2c) . Taken together, these data demonstrate that it is primarily Pgp and not BCRP that is functional in the docetaxel selected DU145 cells, consistent with their respective plasma membrane and cytoplasmic localizations in these cells. Similar results are observed with the DU145/Pac series (not shown).
Since the SP fraction can contain stem-like cells, we also evaluated both the wt and paclitaxeland docetaxel-resistant cells for the expression of several stem cell markers via FACS, including CD44, CD49f, and CD133. Anywhere from 28-66% of DU145 cells have been reported to be CD44+ by different investigators (Patrawala et al., 2006; Stuelten et al., 2010) . In our hand, between78-88% of wt and taxane-resistant cells are CD44+ (Fig 3) , while almost all of them appear to express CD49f on their cell surface (data not shown). Given the rarity of stem cells, only a small fraction of the above are likely to be 'stem-like' in our panel of cell lines, if they exist at all. Collins et al used another marker, CD133, to identify cancer stem cells in human prostate tumors; 0.1% of the prostate cells were found to be CD44+CD133+ and harbored a subpopulation with self-renewal properties (Collins et al., 2005) . Among the DU145 cells, only a small fraction (0.87%) has been reported to be CD133+, which would be more consistent with the distribution pattern of a stem-like subpopulation (Stuelten et al., 2010) . We were not able to identify a CD133+ subpopulation among either the wt or the taxane-resistant DU145 cells (Fig   3) . Although we may be able to eventually detect some CD133+ cells with further optimization of our methods, importantly, our data suggest that taxane selection expands the SP population identical, demonstrating that both fractions are equally resistant to paclitaxel (Fig 4c) .
We also sorted the parental DU145/Pac200 cells by cell surface expression of Pgp into Pgp+ and Pgp-fractions (Fig 4d, lower panel) . Again, the IC 50 values of the Pgp+ and Pgp-fractions for paclitaxel are identical (Fig 4e) . Taken together, these data demonstrate that although all DU145/Pac200 cells have the same phenotype of resistance to paclitaxel, they can be associated with different mechanisms of resistance (i.e. Pgp and non-Pgp) within the same cell population This article has not been copyedited and formatted. The final version may differ from this version. (Fig 5a) . By contrast, KML001 at IC 100 can significantly reduce the SP fraction of DU145 cells (Fig 5a) .
The IC 50 values of KML001 for paclitaxel-and docetaxel-resistant DU145 cells are similar, or at most 2-to 3-fold higher, than for the drug-sensitive wt DU145 cells (Table 1) . Since DU145/Pac200 cells have a large SP fraction that can be readily sorted by FACS, we also This article has not been copyedited and formatted. The final version may differ from this version. , 2003) . KML001 induces phosphorylation of γ-H2AX in wt DU145 as well as DU145/Pac200 cells, including the SP and non-SP fractions, and if anything, more γ-H2AX phosphorylation occurs in the SP than the non-SP fractions (Fig 5c, d ). Taken together, the above data demonstrate that, unlike paclitaxel, KML001 is a poor Pgp substrate, and can target both SP and non-SP cells.
Although modulating telomere dynamics represents a potentially attractive therapeutic strategy, alterations in telomerase activity and telomere lengths have also been implicated in resistance to certain cytotoxic agents (Burger and Harnden, 1998; Deschatrette et al., 2004; Ishibashi and Lippard, 1998; Smith et al., 2009) . Therefore, we investigated whether any changes in telomerase activity and/or telomere lengths occurred in our panel of taxane-resistant prostate cancer cells. Telomere restriction fragment (TRF) length analysis showed that in the prostate cancer cells examined, including paclitaxel-and docetaxel-resistant lines, telomeres are short (2 to 3 kb) and essentially do not change as a consequence of drug selection (Table 1) . Telomerase activity also does not change with selection for resistance to either paclitaxel or docetaxel (Table   1) . Thus, although DU145 cells can be selected for high levels of resistance to the taxanes, their telomere dynamics are minimally affected, and they remain amenable to telomere targeting.
This article has not been copyedited and formatted. The final version may differ from this version. Fig 6a and data not shown) . We also evaluated the relative integrity of telomeres in response to various treatments via FACS-coupled FISH. The ability of the FAMlabeled telomere-specific probe to detect telomeres in metaphase spreads of DU145 cells is shown in Fig 6b. It is apparent that a 72 hour incubation with KML001 or KML001 plus paclitaxel at IC50 concentrations leads to further telomere shortening, whereas paclitaxel alone has minimal effects (Fig 6c, d ).
Combining KML001 with paclitaxel or docetaxel at their fixed IC 50 ratios as per the method of (Table 2 ). Also shown in Table 2 are the calculated dosereduction index (DRI) values, which are a measure of the -fold reduction in dose of each drug in a combination to obtain the same therapeutic effect as with the individual drugs alone (Chou, 2008) . Thus, for both wt and drug resistant DU145 cells a several fold reduction in paclitaxel or docetaxel dose is predicted when either is combined with KML001.
This article has not been copyedited and formatted. The final version may differ from this version. However, the calculated DRI values suggest that LNCaP cells are more sensitive to the taxanes when they are combined with KML001 than C81 cells (Table 2) .
Although at present we do not know the specific molecular pathway(s) contributing to the (Fig 2) , which is consistent with the proportion of Pgp-expressing taxaneresistant cells present in these populations.
This article has not been copyedited and formatted. The final version may differ from this version. Pgp-positive or cell surface Pgp-negative fractions, the sorted fractions are equally resistant to paclitaxel (Fig 4) . Thus, both Pgp and non-Pgp mechanisms of resistance may be associated with DU145 cells exposed to taxanes. Conceivably, an individual cell may employ one or more than one such mechanism of resistance. Such plasticity in response to taxane selection within the same DU145 cell population would not be apparent had only total cell lysates been analyzed by Western blots (e.g., Fig 1a) . changes in telomerase activity; such alterations appear to be dependent on cell type and the specific agents to which cells develop acquired resistance (Burger AM and Harnden, 1998; Deschatrette et al., 2004; Ishibashi and Lippard, 1998; Smith et al., 2009) . Our panel of drugresistant DU145 cells continue to maintain short telomeres irrespective of the taxane (paclitaxel or docetaxel) used for selection, or the levels of resistance acquired by the drug-selected cells (Table 1) . Moreover, total telomerase activity does not appear to be altered between wt and taxane-resistant cells (Table 1) , although it is up to 2-fold higher in the SP compared to the non-SP fractions of the highly resistant DU145/Pac200 cells (data not shown). Taken together, these data suggest that targeting telomeres, particularly with an agent that is also a poor Pgp substrate, should be effective against both Pgp-expressing and Pgp-nonexpressing taxane-resistant prostate cancer cells. Consistent with these observations, KML001 retains significant activity in the taxane-resistant cells, targeting both the SP and non-SP fractions (Fig 5b-d) .
Although telomere lengths and telomerase activity are not affected by drug selection, importantly KML001 or KML001 in combination with paclitaxel can significantly reduce hTERT gene expression and also cause erosion of telomeres (Fig 6) . Drug combination studies reveal that KML001 is synergistic with either paclitaxel or docetaxel in both taxane-resistant and wt DU145 cells (Fig 7, Table 2 ). Such synergism is also observed in the androgen-sensitive LNCaP cells, and in the androgen-insensitive LNCaP/C81 cells grown in phenol red-free media supplemented with charcoal stripped serum (i.e., androgen-deprived conditions) ( Table 2) . KML001 is an orally bioavailable trivalent arsenical compound. A paradigm for using arsenicals in clinical practice exists for another trivalent arsenical, i.e. arsenic trioxide (ATO), which is approved for patients with acute promyelocytic leukemia (APL) who relapse after initial therapies (Soignet et al., 1998; Soignet et al., 2001) . ATO is also being incorporated as part of consolidation therapy for the initial treatment of APL (Powell et al., 2010) . Further, a recent study has piloted the use of ATO as monotherapy for patients with newly diagnosed APL (Ghavamzadeh et al., 2011 being in the µM range (Ajana et al., 2009) . Pharmacokinetic studies reveal that such plasma concentrations can be achieved in patients treated with ATO at the recommended doses for APL (Shen et al., 2001; Fox et al., 2008 
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